Department of Error (DOI:10.1016/S0140-6736(08)61243-X);The power to TRANSCEND

The Lancet

Volumn 372, Issue 9644, 2008, Pages 1128-1130

  Ripley, Toni L ^a   Harrison, Donald ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PERINDOPRIL; PLACEBO; TELMISARTAN; TRANDOLAPRIL;

ANGIONEUROTIC EDEMA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HOSPITAL READMISSION; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; RISK REDUCTION; STROKE;

EID: 52949126979     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61585-8     Document Type: Erratum

References (11)

1. Jorde U.P., Ennezat P.V., Lisker J., et al. Maximally recommended doses of angiotensin-converting-enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 101 (2000) 844-846
2. McKelvie R.S., Yusuf S., Pericak D., et al., for the RESOLVD Pilot Study Investigators. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation 100 (1999) 1056-1064
3. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 342 (2000) 145-153
4. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet (2008) 10.1016/S0140-6736(08)61242-8 published online Aug 31.
5. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
6. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
7. The Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
8. Granger C.B., McMurray J.J.V., Yusuf S., et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 (2003) 772-776
9. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al., for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
10. Kahn N., and McAlister F.A. Re-examining the efficacy of β-blockers for the treatment of hypertension: a meta-analysis. CMAJ 174 (2006) 1737-1742
11. Mochizuki S., Dahlöf B., Shimizu M., et al., for the Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 369 (2007) 1431-1439